A phase III study to evaluate first-line maintenance treatment with Rubraca + Opdivo, Rubraca, Opdivo and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy

Trial Profile

A phase III study to evaluate first-line maintenance treatment with Rubraca + Opdivo, Rubraca, Opdivo and placebo in newly diagnosed patients with stage III/IV high-grade ovarian, fallopian tube, or primary peritoneal cancer who have completed platinum-based chemotherapy

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Nivolumab (Primary) ; Rucaparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Clovis Oncology
  • Most Recent Events

    • 02 Aug 2017 According to a Clovis Oncology media release, apart from the U.S., Europe the trial could possibly conducted in additional countries.
    • 02 Aug 2017 According to a Clovis Oncology media release, the company expects to initiate this trial by the end of 2017.
    • 02 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top